Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants.

Migoya EM, Mistry GC, Stone JA, Comisar W, Sun P, Norcross A, Bi S, Winchell GA, Ghosh K, Uemera N, Deutsch PJ, Wagner JA.

J Clin Pharmacol. 2011 Feb;51(2):202-11. doi: 10.1177/0091270010374853. Epub 2010 Aug 2.

PMID:
20679501
2.

Model-based decision making in early clinical development: minimizing the impact of a blood pressure adverse event.

Stroh M, Addy C, Wu Y, Stoch SA, Pourkavoos N, Groff M, Xu Y, Wagner J, Gottesdiener K, Shadle C, Wang H, Manser K, Winchell GA, Stone JA.

AAPS J. 2009 Mar;11(1):99-108. doi: 10.1208/s12248-009-9083-6. Epub 2009 Feb 6.

3.

The effect of ketoconazole on the pharmacokinetics of a selective alpha 1A-adrenoceptor antagonist.

Winchell GA, Mistry GC, Kari PP, Marbury T, Miller JL, Simpson RC, Rodrigues AD, Gottesdiener KM, Wagner JA.

J Clin Pharmacol. 2005 Jun;45(6):699-703. No abstract available.

PMID:
15901753
4.

Potential for interactions between caspofungin and nelfinavir or rifampin.

Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, Lasseter KC, Kraft WK, Greenberg H, Waldman SA.

Antimicrob Agents Chemother. 2004 Nov;48(11):4306-14.

5.
6.

Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.

Bergshoeff AS, Fraaij PL, van Rossum AM, Verweel G, Wynne LH, Winchell GA, Leavitt RY, Nguyen BY, de Groot R, Burger DM.

Antimicrob Agents Chemother. 2004 May;48(5):1904-7.

7.

Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.

Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Lasseter KC.

Antimicrob Agents Chemother. 2004 Mar;48(3):815-23.

8.

Indinavir and rifabutin drug interactions in healthy volunteers.

Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, Woolf EJ, Kusma SE, Deutsch PJ, Greenberg HE, Waldman SA.

J Clin Pharmacol. 2004 Mar;44(3):305-13.

PMID:
14973305
9.

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA.

Antimicrob Agents Chemother. 2002 Mar;46(3):739-45.

10.

Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency.

Winchell GA, King JD, Chavez-Eng CM, Constanzer ML, Korn SH.

J Clin Pharmacol. 2002 Jan;42(1):61-9.

PMID:
11808825
11.

An extended point-area deconvolution approach for assessing drug input rates.

Yeh KC, Holder DJ, Winchell GA, Wenning LA, Prueksaritanont T.

Pharm Res. 2001 Oct;18(10):1426-34.

PMID:
11697468
12.

Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers.

Saah AJ, Winchell GA, Nessly ML, Seniuk MA, Rhodes RR, Deutsch PJ.

Antimicrob Agents Chemother. 2001 Oct;45(10):2710-5.

13.

Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases.

Rodrigues AD, Winchell GA, Dobrinska MR.

J Clin Pharmacol. 2001 Apr;41(4):368-73.

PMID:
11304892
14.

The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin.

Boruchoff SE, Sturgill MG, Grasing KW, Seibold JR, McCrea J, Winchell GA, Kusma SE, Deutsch PJ.

Clin Pharmacol Ther. 2000 Apr;67(4):351-9.

PMID:
10801243
15.

Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.

Schwartz JI, Van Hecken A, De Schepper PJ, De Lepeleire I, Lasseter KC, Shamblen EC, Winchell GA, Constanzer ML, Chavez CM, Wang DZ, Ebel DL, Justice SJ, Gertz BJ.

J Clin Endocrinol Metab. 1996 Aug;81(8):2942-7.

PMID:
8768856
16.

Plasma concentrations and effect on testosterone metabolism after single doses of MK-0434, a steroid 5 alpha-reductase inhibitor, in healthy subjects.

Van Hecken A, Depré M, Schwartz JI, Tjandramaga TB, Winchell GA, De Lepeleire I, Ng J, De Schepper PJ.

Eur J Clin Pharmacol. 1994;46(2):123-6.

PMID:
8039530
17.

Finasteride, a steroid 5 alpha-reductase inhibitor, does not affect the oxidative metabolism of antipyrine.

Winchell GA, Gregoire S, Taylor AM, Hegland J, Hunninghake DB.

J Clin Pharmacol. 1993 Oct;33(10):967-70.

PMID:
7693768

Supplemental Content

Loading ...
Support Center